共 50 条
- [1] Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy[J]. ONCOTARGET, 2016, 7 (41) : 67521 - 67531Park, HaeseongGarrido-Laguna, IgnacioNaing, AungFu, SiqingFalchook, Gerald S.Piha-Paul, Sarina A.Wheler, Jennifer J.Hong, David S.Tsimberidou, Apostolia M.Subbiah, VivekZinner, Ralph G.Kaseb, Ahmed O.Patel, ShreyaskumarFanale, Michelle A.Velez-Bravo, Vivianne M.Meric-Bernstam, FundaKurzrock, RazelleJanku, Filip
- [2] Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Zibelman, Matthew R.Wong, Yu-NingMalizzia, LoisCorrigan, AlyciaOlszanski, Anthony J.Denlinger, Crystal ShereenRoethke, Susan K.Tetzlaff, Colleen H.Hudes, Gary R.Plimack, Elizabeth R.
- [3] Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)Plimack, Elizabeth R.Wong, Yu-NingMalizzia, LoisCorrigan, AlyciaOlszanski, Anthony J.Denlinger, Crystal ShereenRoethke, SusanTetzlaff, Colleen H.Hudes, Gary R.
- [4] Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors[J]. INVESTIGATIONAL NEW DRUGS, 2015, 33 (05) : 1040 - 1047Zibelman, MatthewWong, Yu-NingDevarajan, KarthikMalizzia, LoisCorrigan, AlyciaOlszanski, Anthony J.Denlinger, Crystal S.Roethke, Susan K.Tetzlaff, Colleen H.Plimack, Elizabeth R.
- [5] Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors[J]. Investigational New Drugs, 2015, 33 : 1040 - 1047Matthew ZibelmanYu-Ning WongKarthik DevarajanLois MalizziaAlycia CorriganAnthony J. OlszanskiCrystal S. DenlingerSusan K. RoethkeColleen H. TetzlaffElizabeth R. Plimack
- [6] A phase I/II study of the oral mTOR inhibitor RAD001 in patients with advanced hematologic malignancies.[J]. BLOOD, 2004, 104 (11) : 287B - 287BYee, KWLWierda, WO'Brien, SThomas, DKurzrock, RFayad, LEHagemeister, FBCortes, JPrestifilippo, KSzatrowski, TPKantarjian, HMGiles, FJ
- [7] A phase I trial of the mTOR inhibitor temsirolimus (TEM) in combination with capecitabine (CAP) in patients with advanced malignancies.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Pishvaian, Michael J.Wang, HongkunHardesty, Rosemarie A.Deeken, John F.He, Aiwu RuthSubramaniam, Deepa SureshZhuang, TingtingMcCarthy, Damian L.Melville, HeatherAlbanese, ChristopherMarshall, JohnHwang, Jimmy J.
- [8] A phase I study of sirolimus (rapamycin) and bevacizumab in patients with advanced malignancies.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)Cohen, E. E.Sharma, M.Janisch, L. A.Stadler, W. M.Kang, S. P.Fleming, G. F.Ratain, M. J.
- [9] Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients[J]. BLOOD, 2013, 122 (21)Janku, FilipGarrido-Laguna, IgnacioVelez-Bravo, VivianneFalchook, Gerald S.Subbiah, VivekHong, David S.Oki, YasuhiroWestin, Jason R.Nunez, Cesar A.Fayad, Luis E.Kwak, Larry W.Shpall, Elizabeth J.Wheler, Jennifer J.Liang, WinnieSalhia, BodourMeric-Bernstam, FundaKurzrock, RazelleFanale, Michelle
- [10] Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Janku, FilipOki, YasuhiroFalchook, Gerald StevenSubbiah, VivekNaing, AungBravo, Vivianne Marie VelezHong, David S.Westin, Jason R.Nunez, CesarFayad, LuisNeelapu, Sattva SwarupKwak, Larry W.Shpall, Elizabeth J.Wheler, Jennifer J.Barnes, TamaraLiang, Winnie S.Salhia, BodourMeric-Bernstam, FundaKurzrock, RazelleFanale, Michelle A.